Eversept Partners, LP Tg Therapeutics, Inc. Transaction History

Eversept Partners, LP

$991 Million
Q4 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $1.52 Million - $2.82 Million	-69,760 Closed	0 $0
Q2 2021 Nov 08, 2023	SELL	$32.5 - $48.96 $22.5 Million - $33.9 Million	-692,829 Reduced 90.85%	69,760 $2.71 Million
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $22.5 Million - $33.9 Million	-692,829 Reduced 90.85%	69,760 $2.71 Million
Q1 2021 Nov 08, 2023	SELL	$41.61 - $54.3 $4.21 Million - $5.5 Million	-101,262 Reduced 11.72%	762,589 $36.8 Million
Q1 2021 May 13, 2021	SELL	$41.61 - $54.3 $4.21 Million - $5.5 Million	-101,262 Reduced 11.72%	762,589 $36.8 Million
Q4 2020 Nov 08, 2023	BUY	$25.27 - $54.9 $21.8 Million - $47.4 Million	863,851 New	863,851 $44.9 Million
Q4 2020 Feb 16, 2021	SELL	$25.27 - $54.9 $4.03 Million - $8.76 Million	-159,479 Reduced 15.58%	863,851 $44.9 Million
Q3 2020 Nov 08, 2023	SELL	$18.49 - $27.24 $27.3 Million - $40.3 Million	-1,477,942 Reduced 59.09%	1,023,330 $27.4 Million
Q3 2020 Nov 13, 2020	SELL	$18.49 - $27.24 $27.3 Million - $40.3 Million	-1,477,942 Reduced 59.09%	1,023,330 $27.4 Million
Q2 2020 Nov 08, 2023	BUY	$8.9 - $21.84 $357,201 - $876,548	40,135 Added 1.63%	2,501,272 $48.7 Million
Q2 2020 Aug 13, 2020	BUY	$8.9 - $21.84 $357,201 - $876,548	40,135 Added 1.63%	2,501,272 $48.7 Million
Q1 2020 Nov 08, 2023	BUY	$7.14 - $15.99 $12 Million - $26.9 Million	1,684,814 Added 217.02%	2,461,137 $24.2 Million
Q1 2020 May 13, 2020	BUY	$7.14 - $15.99 $12 Million - $26.9 Million	1,684,814 Added 217.02%	2,461,137 $24.2 Million
Q4 2019 Nov 08, 2023	BUY	$5.1 - $11.2 $14,392 - $31,606	2,822 Added 0.36%	776,323 $8.62 Million
Q4 2019 Feb 13, 2020	BUY	$5.1 - $11.2 $14,392 - $31,606	2,822 Added 0.36%	776,323 $8.62 Million
Q3 2019 Nov 08, 2023	SELL	$5.38 - $8.99 $591,800 - $988,900	-110,000 Reduced 12.45%	773,501 $4.35 Million
Q3 2019 Nov 13, 2019	SELL	$5.38 - $8.99 $591,800 - $988,900	-110,000 Reduced 12.45%	773,501 $4.34 Million
Q2 2019 Nov 08, 2023	BUY	$6.27 - $8.65 $845,866 - $1.17 Million	134,907 Added 18.02%	883,501 $7.64 Million
Q2 2019 Aug 13, 2019	BUY	$6.27 - $8.65 $845,866 - $1.17 Million	134,907 Added 18.02%	883,501 $7.64 Million
Q1 2019 Nov 08, 2023	BUY	$4.02 - $8.04 $2.75 Million - $5.5 Million	683,594 Added 1051.68%	748,594 $6.02 Million
Q1 2019 May 14, 2019	BUY	$4.02 - $8.04 $2.75 Million - $5.5 Million	683,594 Added 1051.68%	748,594 $6.02 Million
Q3 2018 Nov 08, 2023	SELL	$5.15 - $14.0 $77,250 - $210,000	-15,000 Reduced 18.75%	65,000 $364,000
Q3 2018 Nov 14, 2018	SELL	$5.15 - $14.0 $77,250 - $210,000	-15,000 Reduced 18.75%	65,000 $364,000
Q2 2018 Nov 08, 2023	SELL	$12.5 - $15.0 $875,000 - $1.05 Million	-70,000 Reduced 46.67%	80,000 $1.05 Million
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $875,000 - $1.05 Million	-70,000 Reduced 46.67%	80,000 $1.05 Million
Q1 2018 Nov 08, 2023	BUY	$8.7 - $16.8 $1.31 Million - $2.52 Million	150,000 New	150,000 $2.13 Billion
Q1 2018 May 14, 2018	BUY	$8.7 - $16.8 $1.31 Million - $2.52 Million	150,000 New	150,000 $2.13 Million

Others Institutions Holding TGTX

# of Institutions

371

Shares Held

85.5M

Call Options Held

3.78M

Put Options Held

Vanguard Group Inc Valley Forge, PA

15.6M
Shares

$482 Million
0.01% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$352 Million
0.0% of portfolio
State Street Corp Boston, MA

9.2M
Shares

$284 Million
0.01% of portfolio
Geode Capital Management, LLC Boston, MA

3.19M
Shares

$98.6 Million
0.01% of portfolio
Pictet Asset Management Holding Sa Carouge, V8

2.79M
Shares

$86.3 Million
0.09% of portfolio

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.49B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account